Viral Disease News and Research

RSS

Medivir AB announces license agreement with Daewoong Pharmaceutical for MIV-210 drug

Medivir AB (Sweden) today announced a license agreement with Daewoong Pharmaceutical Co. Ltd., (South Korea) for its hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210).

12 Mar 2010

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

FDA warns about drug mix-ups; drug maker agrees to name change to avoid confusion

The U.S. Food and Drug Administration today warned consumers about the potential for serious side effects from mistakenly using Maalox Total Relief instead of other Maalox products. The two products are intended for the relief of different symptoms and contain different active ingredients.

18 Feb 2010

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

The National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a five-year contract totaling $15,254,919 to Tulane University for its ongoing efforts to treat and prevent Lassa fever, an often deadly viral disease that threatens hundreds of thousands of people annually in West Africa and is classified as a potential bioterrorism threat.

10 Feb 2010

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.

9 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

Within a virus's tiny exterior is a store of energy waiting to be unleashed. When the virus encounters a host cell, this pent-up energy is released, propelling the viral DNA into the cell and turning it into a virus factory.

6 Feb 2010

Closing funding gap for federal viral hepatitis education, screening and surveillance programs stops liver cancer

With most liver cancer caused by undetected or untreated hepatitis B or C viral infection, the 22,000 new cases of liver cancer that are diagnosed each year could be dramatically reduced if Congress took decisive action to close the funding gap for federal viral hepatitis education, screening, and surveillance programs, the National Viral Hepatitis Roundtable (NVHR) said today.

4 Feb 2010

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

Researchers at National Jewish Health have discovered how the virulent food-borne bacteria Listeria monocytogenes induces infected immune cells to sabotage their own defensive response.

2 Feb 2010

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

A new therapeutic made from tobacco plants has been shown to arrest West Nile virus infection, according to a new study by Arizona State University scientist Qiang Chen and his colleagues.

2 Feb 2010

FDA approves neurostimulation treatment for heart failure

The FDA recently approved the first study of neurostimulation as a treatment for heart failure, a chronic disease that affects nearly six million Americans and is the leading cause of hospitalization in America.

2 Feb 2010

USPTO allows claims to Rosetta Genomics' two microRNA related patent applications

Rosetta Genomics today announced that the United States Patent and Trademark Office has allowed claims in two patent applications.

30 Jan 2010

Findings could guide in developing more effective vaccines for HIV/AIDS and cancer

In an acute viral infection, most of the white blood cells known as T cells differentiate into cells that fight the virus and die off in the process. But a few of these "effector" T cells survive and become memory T cells, ensuring that the immune system can respond faster and stronger the next time around.

29 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Researchers at The Scripps Research Institute have discovered a potential new way to stimulate the immune system to prevent or clear a viral infection. By blocking the action of a key protein in the mouse immune system, they were able to boost immune "memory" in those mice-work that may one day help doctors increase the effectiveness of human vaccines designed to prevent viral infections.

28 Jan 2010

Findings offer potential significance to the recovery of walking after spinal cord injury

Researchers at the medical university Karolinska Institutet have created a genetically modified mouse in which certain neurons can be activated by blue light. Shining blue light on brainstems or spinal cords isolated from these mice produces walking-like motor activity. The findings, which are published in the scientific journal Nature Neuroscience, are of potential significance to the recovery of walking after spinal cord injury.

22 Jan 2010

Viral Disease News and Research

Medivir AB announces license agreement with Daewoong Pharmaceutical for MIV-210 drug

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Viral infection can suppress immune response to secondary bacterial infection

FDA warns about drug mix-ups; drug maker agrees to name change to avoid confusion

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

Closing funding gap for federal viral hepatitis education, screening and surveillance programs stops liver cancer

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

FDA approves neurostimulation treatment for heart failure

USPTO allows claims to Rosetta Genomics' two microRNA related patent applications

Findings could guide in developing more effective vaccines for HIV/AIDS and cancer

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Findings offer potential significance to the recovery of walking after spinal cord injury

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News